^
Association details:
| Biomarker: | EGFR exon 19 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Conmana (icotinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Icotinib versus chemotherapy as adjuvant treatment for stage II–IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Published date:
07/16/2021
Excerpt:
...confirmed activation mutation in exon 19 or exon 21 of the EGFR gene...receive either oral icotinib 125 mg thrice daily for 2 years or four 21-day cycles of intravenous chemotherapy...Median disease-free survival was 47·0 months (95% CI 36·4–not reached) in the icotinib group and 22·1 months (16·8–30·4) in the chemotherapy group...icotinib significantly improves disease-free survival and has a better tolerability profile in patients with EGFR-mutant stage II–IIIA NSCLC...
Secondary therapy:
cisplatin + vinorelbine tartrate; cisplatin + pemetrexed
DOI:
https://doi.org/10.1016/S2213-2600(21)00134-X
Trial ID:
Source:
Title:
Effects of Icotinib on Advanced Non-Small Cell Lung Cancer with Different EGFR Phenotypes
Excerpt:
Clinical data of patients with advanced non-small cell lung cancer who received Icotinib treatment...Median PFS of exon 19 mutated mutant patients was 11.3 months, mean PFS of exon 21 L858R mutated mutant patients was 8.7 months (P = 0.3145)....Icotinib has great efficacy in EGFR mutated patients, making it an optimal regimen to treat EGFR mutated patients.
DOI:
10.1007/s12013-014-9955-y
